Zydus receives final approval from the USFDA for Carbamazepine Extended-Release Tablets USP

Deepthi | Myequity news | Date : 08-02-2019 12:08:00 IST

Zydus Cadila has received the final approval from the USFDA to market Carbamazepine Extended-Release Tablets USP (USRLD—TegretolXR), 100mg, 200mg, and 400mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Carbamazepine is an anticonvulsantagent. It works by reducing excessive nerve signals in the braina nd restoring the normal balance of nerve activity. This medication is used to treat certain types of seizures (partial, generalized tonic-clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngealneuralgia).


More from Myequity